Beiersdorf prelim sales, earnings down in 2009
This article was originally published in The Rose Sheet
Executive Summary
Hamburg, Germany-based firm records preliminary sales of €5.7 bil. ($8.3 bil.) for fiscal 2009, down 3.6 percent from the year prior. Sales in its consumer business segment, which includes Eucerin and NIVEA brands, were down 2.2 percent to €5.01 bil. ($7.2 bil.), though organic sales of the unit increased 1.2 percent. Although sales in Western Europe declined, revenues in the U.S., China and Latin America rose. Profit after taxes fell 33 percent to €379 mil. ($544.8 mil.). Beiersdorf's final results for the fiscal year will be released at an analyst meeting March 4
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.